Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 12/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.59 |
| ▸ | PRKACA | P17612 | 10/20 | 0.56 |
| ▸ | GSK3B | P49841 | 10/20 | 0.56 |
| ▸ | RPS6KA5 | O75582 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715626 | 0.78 | RPS6KA5 (0.65) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 | |
| SCHEMBL6401655 | 0.74 | RPS6KB1 (1.00) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 | |
| SCHEMBL4714655 | 0.74 | ROCK1 (0.66) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 | |
| SCHEMBL14252576 | 0.74 | RPS6KA5 (0.60) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 | |
| SCHEMBL4718814 | 0.71 | RPS6KA5 (1.00) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 | |
| SCHEMBL6405625 | 0.69 | RPS6KB1 (1.00) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 | |
| SCHEMBL4714229 | 0.68 | ROCK1 (0.68) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 | |
| SCHEMBL6407241 | 0.68 | RPS6KB1 (0.84) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 | |
| SCHEMBL4717559 | 0.68 | RPS6KA5 (0.93) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 | |
| SCHEMBL4716563 | 0.68 | RPS6KA5 (0.98) | RPS6KB1ROCK1PRKACAGSK3BRPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | RPS6KB1 668/4885ROCK1 846/4885PRKACA 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.